Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation
Journal of Gastroenterology and Hepatology · 2024-11 · 39 (11) · 2272-2280
DOI: 10.1111/jgh.16693 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 07.08.2024. Verfasst von Xu Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Medical Sciences, Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Shanxi Provincial Key Laboratory of Digestive Diseases and Organ Transplantation, Scientific and Technological Innovation Base for Evaluation of Immune Rejection after Liver Transplantation, Natural Science Foundation of Shanxi Province.
Abstract (Originalsprache)
Liver transplantation (LT) is an effective method for curing hepatocellular carcinoma (HCC). However postoperative tumor recurrence can lead to higher mortality rates. To select suitable candidates for LT, the Milan Criteria (MC) were first proposed based on tumor morphological characteristics. For those patients who meet the MC, the MC can effectively reduce the postoperative tumor recurrence rate and improve the prognosis of patients undergoing LT. It has always been internationally recognized as the gold standard for selecting candidates for LT, marking a milestone in the history of LT for HCC. However, its strict conditions exclude some HCC patients who could benefit from LT. Therefore, comprehension consideration criteria, including serum biomarkers, tumor histology, and other factor, have been continuously proposed in addition to tumor morphology. This article summaries the prediction model for HCC recurrence after LT from five aspects: tumor morphology, serum markers, histopathology, cellular inflammatory factors and downstaging treatment before transplantation. The aim is to assist clinicians in accurately assessing HCC status, selecting appropriate liver transplant candidates, maximize graft and patients' survival, and optimizing the utilization of social health resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academy of Medical Sciences, Shanxi Medical University, Taiyuan, China.
- Department of Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
- Hepatobiliary and Pancreatic Surgery and Liver Transplantation Center, First Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Xu Zhang
Förderung
- Shanxi Provincial Key Laboratory of Digestive Diseases and Organ Transplantation
- Scientific and Technological Innovation Base for Evaluation of Immune Rejection after Liver Transplantation
- Natural Science Foundation of Shanxi Province
Zitieren
APA
Zhang, X., Chen, C., Wang, Y., & Xu, J. (2024). Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation. Journal of Gastroenterology and Hepatology, 39(11), 2272-2280. https://doi.org/10.1111/jgh.16693
Vancouver
Zhang X, Chen C, Wang Y, Xu J. Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation. Journal of Gastroenterology and Hepatology. 2024;39(11):2272-2280. doi:10.1111/jgh.16693
BibTeX
@article{Zhang2024,
author = {Zhang, Xu and Chen, Chi and Wang, Yan and Xu, Jun},
title = {Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
volume = {39},
number = {11},
pages = {2272--2280},
doi = {10.1111/jgh.16693}
}
EUVIMED